Within the last quarter, Zentalis Pharma ZNTL has observed the following analyst ratings:

In the last 3 months, 8 analysts have offered 12-month price targets for Zentalis Pharma. The company has an average price target of $50.75 with a high of $70.00 and a low of $38.00.

Below is a summary of how these 8 analysts rated Zentalis Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average represents a 22.32% decrease from the previous average price target of $65.33.

Stay up to date on Zentalis Pharma analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.